Moleculin Biotech Inc. (MBRX) is priced at $0.96 after the most recent trading session. At the very opening of the session, the stock price was $0.774 and reached a high price of $0.7815, prior to closing the session it reached the value of $0.78. The stock touched a low price of $0.7438.
Recently in News on December 1, 2020, Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066. Priority Review Vouchers subject to approved NDA. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Moleculin Biotech Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $1.9700 on 04/08/20, with the lowest value was $0.3230 for the same time period, recorded on 03/16/20.
Moleculin Biotech Inc. (MBRX) full year performance was -27.78%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Moleculin Biotech Inc. shares are logging -51.45% during the 52-week period from high price, and 196.13% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.32 and $1.97.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 41116889 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Moleculin Biotech Inc. (MBRX) recorded performance in the market was -14.76%, having the revenues showcasing -11.04% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 48.98M, as it employees total of 11 workers.
The Analysts eye on Moleculin Biotech Inc. (MBRX)
During the last month, 0 analysts gave the Moleculin Biotech Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.8749, with a change in the price was noted +0.1233. In a similar fashion, Moleculin Biotech Inc. posted a movement of +14.41% for the period of last 100 days, recording 2,463,435 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for MBRX is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical rundown of Moleculin Biotech Inc. (MBRX)
Raw Stochastic average of Moleculin Biotech Inc. in the period of last 50 days is set at 57.53%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 55.78%. In the last 20 days, the company’s Stochastic %K was 60.61% and its Stochastic %D was recorded 62.21%.
Considering, the past performance of Moleculin Biotech Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -14.76%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -31.58%, alongside a downfall of -27.78% for the period of the last 12 months. The shares increased approximately by -5.87% in the 7-day charts and went down by 8.35% in the period of the last 30 days. Common stock shares were lifted by -11.04% during last recorded quarter.